127 related articles for article (PubMed ID: 30696623)
1. Olaratumab for STS Disappoints in Phase III.
Cancer Discov; 2019 Mar; 9(3):312-313. PubMed ID: 30696623
[TBL] [Abstract][Full Text] [Related]
2. Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial.
Tap WD; Jones RL; Van Tine BA; Chmielowski B; Elias AD; Adkins D; Agulnik M; Cooney MM; Livingston MB; Pennock G; Hameed MR; Shah GD; Qin A; Shahir A; Cronier DM; Ilaria R; Conti I; Cosaert J; Schwartz GK
Lancet; 2016 Jul; 388(10043):488-97. PubMed ID: 27291997
[TBL] [Abstract][Full Text] [Related]
3. Olaratumab for advanced soft tissue sarcoma.
Tobias A; O'brien MP; Agulnik M
Expert Rev Clin Pharmacol; 2017 Jul; 10(7):699-705. PubMed ID: 28447475
[TBL] [Abstract][Full Text] [Related]
4. Olaratumab: a platelet-derived growth factor receptor-α-blocking antibody for the treatment of soft tissue sarcoma.
Pender A; Jones RL
Clin Pharmacol; 2017; 9():159-164. PubMed ID: 29270033
[TBL] [Abstract][Full Text] [Related]
5. Olaratumab's failure in soft tissue sarcoma.
Bou Zerdan M; Bidikian AH; Alameh I; Nakib CE; Assi HI
Rare Tumors; 2021; 13():20363613211034115. PubMed ID: 34349891
[TBL] [Abstract][Full Text] [Related]
6. Investigating a chimeric anti-mouse PDGFRα antibody as a radiosensitizer in primary mouse sarcomas.
Song EJ; Ashcraft KA; Lowery CD; Mowery YM; Luo L; Ma Y; Campos LDS; Cardona DM; Stancato L; Kirsch DG
EBioMedicine; 2019 Feb; 40():224-230. PubMed ID: 30711517
[TBL] [Abstract][Full Text] [Related]
7. Olaratumab for the treatment of soft tissue sarcoma.
Deshpande HA; Cecchini M; Ni Choileain S; Jones R
Drugs Today (Barc); 2017 Apr; 53(4):247-255. PubMed ID: 28492292
[TBL] [Abstract][Full Text] [Related]
8. Olaratumab: A Novel Platelet-Derived Growth Factor Receptor α-Inhibitor for Advanced Soft Tissue Sarcoma.
Andrick BJ; Gandhi A
Ann Pharmacother; 2017 Dec; 51(12):1090-1098. PubMed ID: 28778132
[TBL] [Abstract][Full Text] [Related]
9. Developments in the management of advanced soft-tissue sarcoma - olaratumab in context.
Moroncini G; Maccaroni E; Fiordoliva I; Pellei C; Gabrielli A; Berardi R
Onco Targets Ther; 2018; 11():833-842. PubMed ID: 29497315
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on olaratumab in the treatment of soft-tissue sarcoma: design, development, and place in therapy.
Davis EJ; Chugh R
Drug Des Devel Ther; 2017; 11():3579-3587. PubMed ID: 29263653
[TBL] [Abstract][Full Text] [Related]
11. Olaratumab: First Global Approval.
Shirley M
Drugs; 2017 Jan; 77(1):107-112. PubMed ID: 27995580
[TBL] [Abstract][Full Text] [Related]
12. Olaratumab for the treatment of advanced soft tissue sarcoma.
Okuno SH; Maran A; Robinson SI
Expert Rev Anticancer Ther; 2017 Oct; 17(10):883-887. PubMed ID: 28862476
[TBL] [Abstract][Full Text] [Related]
13. Olaratumab plus anthracyline in advanced/metastatic soft tissue sarcoma : Data of real-world utilization in Austria.
Seeber A; Weiss L; Romeder F; Szkandera J; Kuehr T; Kostner S; Pichler P; Jaeger T; Kocher F; Greil R; Brodowicz T
Wien Klin Wochenschr; 2021 Jan; 133(1-2):21-25. PubMed ID: 31620878
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic Modeling of Olaratumab, an Anti-PDGFRα Human Monoclonal Antibody, in Patients with Advanced and/or Metastatic Cancer.
Mo G; Baldwin JR; Luffer-Atlas D; Ilaria RL; Conti I; Heathman M; Cronier DM
Clin Pharmacokinet; 2018 Mar; 57(3):355-365. PubMed ID: 28620891
[TBL] [Abstract][Full Text] [Related]
15. Olaratumab Exerts Antitumor Activity in Preclinical Models of Pediatric Bone and Soft Tissue Tumors through Inhibition of Platelet-Derived Growth Factor Receptor α.
Lowery CD; Blosser W; Dowless M; Knoche S; Stephens J; Li H; Surguladze D; Loizos N; Luffer-Atlas D; Oakley GJ; Guo Q; Iyer S; Rubin BP; Stancato L
Clin Cancer Res; 2018 Feb; 24(4):847-857. PubMed ID: 29191969
[No Abstract] [Full Text] [Related]
16. Olaratumab Approved for Soft-Tissue Sarcoma.
Cancer Discov; 2016 Dec; 6(12):1297. PubMed ID: 27827816
[TBL] [Abstract][Full Text] [Related]
17. Olaratumab in the management of advanced soft tissue sarcoma.
Zobniw CM; Trinh VA; Posey K; Somaiah N
J Oncol Pharm Pract; 2019 Mar; 25(2):442-448. PubMed ID: 30032714
[TBL] [Abstract][Full Text] [Related]
18. Olaratumab for the treatment of soft-tissue sarcoma.
Pender A; Jones RL
Future Oncol; 2017 Oct; 13(24):2151-2157. PubMed ID: 28745071
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer.
McGuire WP; Penson RT; Gore M; Herraez AC; Peterson P; Shahir A; Ilaria R
BMC Cancer; 2018 Dec; 18(1):1292. PubMed ID: 30591028
[TBL] [Abstract][Full Text] [Related]
20. Olaratumab in Combination with Doxorubicin for the Treatment of Advanced Soft Tissue Sarcoma: An Evidence Review Group Perspective of a National Institute for Health and Care Excellence Single Technology Appraisal.
Tikhonova IA; Jones-Hughes T; Dunham J; Warren FC; Robinson S; Stephens P; Hoyle M
Pharmacoeconomics; 2018 Jan; 36(1):39-49. PubMed ID: 28914440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
